
==== Front
Transl Oncol
Transl Oncol
Translational Oncology
1936-5233
Neoplasia Press

S1936-5233(24)00223-7
10.1016/j.tranon.2024.102096
102096
Review Article
Multifaceted role of GCN2 in tumor adaptation and therapeutic targeting
Chen Can ab
Xie Yaping syxieyp@163.com
ab⁎
Qian Shenxian sxqian1028@zju.edu.cn
ab⁎
a Department of Hematology, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou, China
b Zhejiang University, School of Medicine, Hangzhou, China
⁎ Corresponding authors at: Department of Hematology, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou, China. syxieyp@163.comsxqian1028@zju.edu.cn
22 8 2024
11 2024
22 8 2024
49 10209631 5 2024
26 7 2024
11 8 2024
© 2024 The Authors. Published by Elsevier Inc.
2024

https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Highlights

• A thorough review of research on GCN2 has been conducted, offering a detailed overview of its multifaceted impacts on cellular processes.

• Through pan-cancer analysis, further investigation was carried out on the diverse roles of GCN2 in various tumor prognoses, exploring its relationship with immune responses and potential effects on immunotherapy outcomes.

• A comprehensive survey of current GCN2 inhibitors was performed, compiling findings from both in vitro and in vivo studies.

Tumor cells voraciously consume nutrients from their environment to facilitate rapid proliferation, necessitating effective strategies to manage nutrient scarcity during tumor growth and progression. A pivotal regulatory mechanism in this context is the Integrated Stress Response (ISR), which ensures cellular homeostasis under conditions such as endoplasmic reticulum stress, the unfolded protein response, and nutrient deprivation. Within the ISR framework, the kinase GCN2 is critical, orchestrating a myriad of cellular processes including the inhibition of protein synthesis, the enhancement of amino acid transport, autophagy initiation, and angiogenesis. These processes collectively enable tumor survival and adaptation under nutrient-limited conditions. Furthermore, GCN2-mediated pathways may induce apoptosis, a property exploited by specific therapeutic agents. Leveraging extensive datasets from TCGA, GEO, and GTEx projects, we conducted a pan-cancer analysis to investigate the prognostic significance of GCN2 expression across diverse cancer types. Our analysis indicates that GCN2 expression significantly varies and correlates with both adverse and favorable prognoses depending on the type of cancer, illustrating its complex role in tumorigenesis. Importantly, GCN2 also modulates the tumor immune microenvironment, influencing immune checkpoint expression and the functionality of immune cells, thereby affecting immunotherapy outcomes. This study highlights the potential of targeting GCN2 with specific inhibitors, as evidenced by their efficacy in preclinical models to augment treatment responses and combat resistance in oncology. These findings advocate for a deeper exploration of GCN2′s multifaceted roles, which could pave the way for novel targeted therapies in cancer treatment, aiming to improve clinical outcomes.

Keywords

GCN2
Drug resistance
Tumor adaptation
Inhibitor
Pan-cancer
==== Body
pmcIntroduction

To maintain rapid growth under nutrient-poor conditions, tumor cells modify their metabolic pathways to reconcile the heightened need for biomass production with energy generation [1]. A key regulatory mechanism in this adaptation is the Integrated Stress Response (ISR), which maintains cellular equilibrium under various stresses such as endoplasmic reticulum stress, the unfolded protein response, and nutrient shortages [2]. The ISR initiates through the phosphorylation of eIF-2α at serine‑51, controlled by four specific kinases: heme-regulated initiation factor-2α kinase, dsRNA-activated protein kinase (PKR), PKR-like endoplasmic reticulum kinase, and general control nonderepressible 2 (GCN2) [2]. Among these, GCN2, encoded by the EIF2AK4 gene, is essential, serving as a direct link between nutrient availability and protein stability[3].

GCN2 activation occurs primarily during amino acid scarcity and features a multi-domain structure, including a standard eukaryotic protein kinase catalytic domain, a histidyl-tRNA synthetase-like domain, and a C-terminal ribosome domain [[4], [5], [6]]. When active, GCN2 phosphorylates eIF2α, reducing overall protein synthesis but enhancing the translation of specific mRNAs, such as ATF4. ATF4 is crucial in regulating the expression of genes that maintain cellular homeostasis, affect protein metabolism, and manage responses to various physiological and pathological conditions [7].

Recent research underscores GCN2′s role in mediating interactions between different pathways within tumors, highlighting its potential as a cancer therapy target. This review offers a detailed analysis of GCN2′s role in cancer, exploring its mechanisms across different tumor types and stress conditions, and includes a pan-cancer analysis of GCN2. We also review existing GCN2 inhibitors and their preclinical evaluations. Significantly, GCN2 not only impacts tumor cells but also influences the tumor immune microenvironment, emphasizing the importance of understanding GCN2′s roles to develop effective cancer treatments, including immunotherapies.

GCN2′s key role in the protection of cancer cells

GCN2 kinase has emerged as a critical regulator in cancer biology, playing a pivotal role in cellular adaptation to environmental and metabolic stressors [8]. As a crucial sensor of amino acid availability, GCN2 orchestrates a comprehensive response to nutrient deprivation, a common challenge faced by rapidly proliferating tumor cells. GCN2 preserves cellular homeostasis by modulating protein synthesis [[9], [10], [11]], upregulating amino acid transporters [10,[12], [13], [14]], promoting autophagy [15,16] and enhancing the efficiency of scarce amino acids for protein synthesis [17]. When cells face MYC-induced proteotoxicity [18,19] or other forms of nutrient scarcity, GCN2′s activation promotes angiogenesis [20,21], oversees mitochondrial quality control [[22], [23], [24]] and boosts ribosome biogenesis [25,26]. These functions underscore GCN2’s pivotal role in preserving cellular stability and promoting tumorigenesis.

Maintaining cellular homeostasis

Reducing global protein synthesis

GCN2 plays a crucial role in cellular adaptation to nutrient stress by modulating protein synthesis and amino acid metabolism [[9], [10], [11]]. Under conditions of amino acid scarcity, GCN2 enhances ATF4 expression, which subsequently induces the production of the stress response protein Sestrin2. This protein plays a crucial role in maintaining mTORC1 repression by preventing its localization to the lysosome, ultimately leading to a significant reduction in global protein synthesis [27]. This adaptation is vital for maintaining stable amino acid levels, crucial for tumor cell survival. For instance, in human colorectal carcinoma cells, deprivation of external arginine activates the GCN2 pathway, reducing protein synthesis through mTOR signaling inhibition[9]. Similarly, in hepatocellular carcinoma, restricting arginine availability decreases mRNA and protein levels, but these effects are reversible by inhibiting GCN2, which then promotes cellular senescence [10]. Proline deprivation in melanoma cells also activates GCN2, reducing protein synthesis [11]. Furthermore, treatment with ixazomib in certain cancer cells leads to amino acid depletion, GCN2 activation, and subsequent suppression of protein synthesis, demonstrating how GCN2 can respond to different metabolic stresses to regulate tumor survival [28] (Fig. 1).Fig. 1 GCN2′s Protective Mechanism in Tumor Cells. GCN2 activation can be triggered by various stressors, including proteotoxicity due to MYC overactivation, impaired protein degradation from VCP/P97 inhibition, or amino acid scarcity caused by certain experimental conditions or drugs. This leads to the accumulation of uncharged tRNA, which activates GCN2. Energy deficits, indicated by inhibited mitochondrial ATP synthase or LDHA, as well as reduced expression of MIC60 in the mitochondrial inner membrane or TRAP1 under nutrient-deficient conditions, can also activate GCN2. Once activated, GCN2 enhances cell survival through several pathways: it inhibits the mTOR pathway, decreases ribosome formation, and phosphorylates eIF2α to reduce protein synthesis. Additionally, GCN2 activates the MEK/ERK and AKT pathways. It activates genes downstream of ATF4, improving the cell's ability to acquire amino acids and survive. GCN2 also regulates mitosis to maintain genomic stability, avoids IFN-induced cellular damage by downregulating IFNAR1, and may decrease apoptosis by inhibiting the JNK/P38 pathway, thereby promoting cell survival.

Fig. 1

Building on the regulatory mechanisms of GCN2, MYC, a pivotal oncogene in cancer metabolism, drives cell growth and proliferation by manipulating similar metabolic pathways. MYC indirectly activates GCN2 kinase by accumulating uncharged tRNAs, leading to ATF4 upregulation [29]. ATF4, working in tandem with MYC, orchestrates the expression of key genes involved in amino acid and protein synthesis, including 4E-BP1. This gene acts as a translation inhibitor, helping to balance protein synthesis and mitigate proteotoxic stress, a common consequence of MYC overexpression [18]. Inhibition of GCN2, achieved through pharmacological agents, increases protein synthesis rates and MYC expression in APC-deficient cells, leading to MYC-induced cell death [19]. This complex interplay highlights the critical role of GCN2 and MYC in regulating protein synthesis and stress response pathways, which are fundamental for the survival and proliferation of cancer cells.

Upregulating of amino acid transporter gene expression

GCN2′s role extends to the regulation of over 60 solute carrier (SLC) genes crucial for amino acid transport, thereby preserving the availability of these vital nutrients for tumor expansion [12]. This regulation ensures the continuous availability of vital nutrients necessary for tumor growth and expansion. In various cancers such as osteosarcoma [13], prostate cancer (PC) [12], hepatocellular carcinoma (HCC) [10], and breast cancer [14], GCN2′s regulatory effect on SLC genes is crucial. In PC, GCN2′s significance is underscored by its influence on a broad array of SLC transporter genes critical especially 4F2 for tumor growth [12]. In osteosarcoma 143B cells, the knockout of ASCT2, key for glutamine uptake, activates GCN2, leading to upregulation of SNAT1 to compensate for ASCT2′s reduced functionality. Silencing GCN2 in these cells results in decreased cell proliferation [13]. In HCC, GCN2 responds to arginine deprivation by upregulating the SLC7A1 transporter, which is essential for arginine uptake and, consequently, cell survival [10]. Similarly, in HeLa cells, kynurenine presence hinders cystine uptake but activates GCN2, enhancing ATF4 translation and SLC7A11 expression, increasing cystine acquisition [14]. These examples highlight GCN2’s sophisticated mechanisms in adapting to amino acid deprivation across different cancer types, illustrating its integral role in maintaining cellular metabolism and promoting cancer cell survival under nutrient-limited conditions.

Regulating autophagy

Amino acids and autophagy share a reciprocal relationship, whereby scarcity of amino acids triggers a signaling cascade that reduces their demand while simultaneously enhancing their intracellular synthesis, recycling, and influx. The GCN2 signaling pathway is central to this process, especially in the regulation of stress-induced expression of autophagy-related genes [5]. Through the activation of its kinase and the downstream transcription factor ATF4, GCN2 significantly increases the transcription of key autophagy proteins. These proteins are essential for various stages of autophagy, including the synthesis (such as ATG5 and ATG12), maturation (like LC3), and turnover of autophagosomes, in response to amino acid deprivation [15]. Additionally, the inhibition of proteins such as HSP70 and VCP/p97 can lead to the activation of GCN2, which plays a protective role in cancer cells by enhancing autophagy and metabolic turnover, thus supporting cellular survival under nutrient-stressed conditions [15,16]. It's important to note that merely increasing gene expression does not automatically activate autophagy. mTORC1 serves as the primary acute regulator of autophagy [30]. A crucial initial step in autophagy is the activation of ULK1. When nutrients are abundant, mTORC1 phosphorylates ULK1, thus preventing its activation by AMPK, which is a key promoter of autophagy [31]. Therefore, the activation of autophagy by GCN2 may be partially achieved through its inhibition of the mTOR pathway [27].

Balancing amino acid utilization

In addition to reducing protein synthesis, promoting autophagy, and enhancing amino acid transport, GCN2 plays a pivotal role in rerouting scarce amino acids from various metabolic pathways to protein synthesis, particularly under conditions of amino acid scarcity. This function is critical for sustaining cell survival and functionality in environments lacking nutrients. Tryptophan, an essential amino acid and the least abundant of those encoded by the genetic code, fulfills roles beyond its basic function as a protein building block [32]. Trp-degrading enzymes are commonly expressed in various cancers because the metabolites of Trp, like IDO1 and TDO2, play significant roles in the tumor's immune evasion tactics [33]. Consequently, cancer cells need to manage the allocation of Trp between its conversion into metabolic products and its use in protein synthesis. In specific cancers such as breast cancer, colon cancer, and B-cell lymphoma, Trp deprivation specifically elevates cytoplasmic WARS protein levels without affecting nuclear or extracellular WARS expression, a response driven by the GCN2-ATF4 axis. According to computational models, a shortage of Trp funnels it towards WARS utilization [17].

Promoting angiogenesis

Amino acid deprivation triggers a notable increase in angiogenesis through upregulated expression of vascular endothelial growth factor (VEGF), facilitated by the GCN2-ATF4 pathway. As tumors face limitations in their blood supply, their need for oxygen and essential nutrients, such as glucose and amino acids, intensifies. An adaptive strategy employed by tumors is to reinitiate their blood supply through the angiogenic switch [34,35]. This phenomenon has been observed in various cancer cell types, including head and neck squamous carcinoma, human oral squamous carcinoma cells, glioblastoma cells, breast cancer cells, and lung carcinoma cells. In these cells, a significant elevation in VEGF expression occurs in response to amino acid deprivation, mediated by GCN2 activation [20,21]. Additionally, studies have shown that the knockdown of GCN2 in tumor cells leads to reduced tumor growth and angiogenesis in vivo, underscoring the pivotal role of the GCN2/ATF4 pathway in enabling tumor adaptation and growth under nutrient-deprived conditions [20].

Mitochondria and GCN2 activation

Mitochondria are pivotal at every stage of oncogenesis, from the initiation of malignant transformation to the progression of metastasis. They not only provide energy but also regulate key survival mechanisms under nutrient stress and therapeutic interventions. The GCN2 kinase pathway is central to these processes, activating complex adaptation strategies in cancer cells facing oxidative damage, nutrient deficiency, and therapeutic stress. In specific cancers, such as colon [36] and gastric cancers [37,38], mitochondrial signals trigger GCN2 activation, which leads to a preferential shift towards glycolysis, reflecting a strategic modulation of energy production to support cellular proliferation and survival. For instance, the inhibition of ATP synthase in colon cancer cells induces a shift to glycolysis through GCN2 activation, showcasing adaptability in energy metabolism [36].

GCN2 is a crucial mediator in mitochondrial quality control. It responds to energy deficits by activating and coordinating mitochondrial-associated genes, such as TNF receptor-associated protein 1 (TRAP1). TRAP1, a member of the mitochondrial HSP90 family, is instrumental in mitigating oxidative stress and preventing apoptosis [39]. When nutrient levels are low, the activation of TRAP1 further stimulates the GCN2-eIF2α pathway, leading to the upregulation of ATF4. This, in turn, boosts the expression of its target genes, BiP/Grp78 and xCT, enhancing the cell's ability to cope with ER stress and oxidative damage [22,23,40]

Furthermore, the role of Lactate dehydrogenase isoform A (LDHA) in cancer cells illustrates another layer of metabolic adaptation. Under hypoxic conditions, LDHA facilitates survival by converting pyruvate to lactate, reducing dependence on mitochondrial oxidation [41]. Inhibition of LDHA can also activate the GCN2-ATF4 pathway, which then enhances the uptake of glutamine and other essential amino acids through the expression of SLC1A5, activating key survival pathways like mTORC1 [23].

Additionally, in the context of cellular architecture, Mic60’s role in sustaining mitochondrial structure is vital for regulating energy dynamics and apoptosis resistance [42]. In prostatic adenocarcinoma, low expression of Mic60 triggers compensatory responses that include GCN2/Akt kinase signaling, essential for maintaining cell viability. Targeting Mic60-deficient tumors with GCN2 inhibitors has shown promise in inducing apoptosis and inhibiting tumor proliferation [24].

This integration of GCN2 signaling with mitochondrial quality control processes links nutrient availability to mitochondrial health, providing a comprehensive framework for understanding the interplay between metabolic demands and cellular adaptation strategies. This insight offers a rich landscape of potential therapeutic targets, highlighting the importance of mitochondrial quality control in determining cellular fate under various stress conditions.

GCN2 and ribosome biogenesis

In the dynamic landscape of cancer cell proliferation, metabolic reprogramming is a pivotal strategy that enhances biomass production, supporting rapid cell growth and division [43]. This shift in metabolism is closely associated with the upregulation of ribosome biogenesis (RiBi), a crucial process for synthesizing the proteins necessary for cellular expansion. GCN2 plays a key role as a modulator of RiBi and cellular metabolic adaptation, particularly in response to the varying nutrient conditions encountered by cancer cells.

GCN2 exerts a dual regulatory effect on ribosome biogenesis in colon cancer cells. Under nutrient scarcity, it curtails the transcription of 47S pre-rRNA, thereby preventing irreversible nucleolar stress and conserving resources essential for maintaining cellular viability during metabolic stress. Conversely, in conditions where nutrients are plentiful, GCN2 activates the transcription of 47S pre-rRNA, facilitating the rapid proliferation typical of cancer cells. This nuanced regulation highlights the potential of combining GCN2 inhibitors with RNA Pol I inhibitors to effectively disrupt cancer cell survival strategies. By shifting their state from cell cycle arrest to apoptosis, these inhibitors can exploit the cells’ dependency on the prevailing nutritional environment [25].

In pancreatic cancer cells, particularly those with activated K-Ras mutations, there is a notable adaptability to nutrient-poor environments, which often involves the scavenging of extracellular proteins to sustain tumor growth. While GCN2 does not directly participate in the scavenging process, it is integral to enabling growth under these challenging conditions(26).

It achieves this through two primary mechanisms: firstly, by modulating translation initiation to prevent ribosome stalling—a common issue in amino acid-depleted conditions [26]. Phosphorylation of eIF2α inhibits the initiation of translation[44], which leads to a decrease in the number of ribosomes actively engaged in translation. Under conditions of leucine deprivation, cells with a GCN2 knockout (GCN2 KO) demonstrate a shift towards polysomes. This accumulation of polysomes in GCN2 KO cells is likely due to ribosome stalling [45]. This indicates that GCN2 is essential for adjusting ribosomal dynamics in response to fluctuations in amino acid availability, thereby preventing the inefficient buildup of stalled ribosomes that occurs in its absence. This modulation is crucial for optimizing the use of limited amino acids for protein synthesis, effectively shifting the bottleneck in translation from elongation to initiation. Secondly, GCN2 selectively enhances the synthesis of proteins necessary for cellular catabolism, such as lysosomal hydrolases, while downregulating the production of anabolic proteins, including those involved in ribosome assembly. This selective synthesis strategy is exemplified by the enzyme cathepsin L, which under GCN2 regulation, demonstrates a high turnover rate in pancreatic cancer cells, indicating its pivotal role in cellular adaptation to nutrient scarcity [26].

Key regulator of mitosis and genomic stability

In the realm of mitosis, GCN2 ensures accurate chromosome alignment and segregation. It achieves this by inhibiting PP1 phosphatases through direct phosphorylation [46]. This inhibition is crucial as it prevents the premature dephosphorylation of mitotic substrates, thus maintaining the integrity of chromosome segregation. This action helps mitigate chromosomal errors and avoid delays in mitosis.

The interaction between GCN2 and mitotic regulation is pivotal in maintaining genomic stability, which is crucial for preventing the propagation of genetic errors in cell division. This role of GCN2 highlights its potential as a target in cancer therapy. Specifically, the combination of GCN2 inhibition with Aurora A kinase inhibitors could amplify therapeutic efficacy, offering a promising strategy for enhancing the effectiveness of cancer treatments [46]. This approach underscores the importance of GCN2 in cancer biology and its potential to improve therapeutic outcomes by ensuring the accuracy and stability of mitotic

Interconnected pathways for ensuring cell survival

In the complex cellular response to amino acid limitation, GCN2 emerges as a crucial sensor, although it is not the only one involved. Research using GCN2-deficient mouse embryo fibroblast cells has demonstrated that GCN2 is essential for the activation of the MEK/ERK pathway under amino acid scarcity. This is particularly evident in hepatocellular carcinoma, where phosphorylation of eIF2 by GCN2 is necessary for the activation of MEK, demonstrating a GCN2-dependent pathway that leads to further phosphorylation of eIF2 and triggers the MEK/ERK signaling cascade [47]. Similar mechanisms have been observed in lung cancer cells, where inhibition of the VCP/p97 complex resulted in the activation of GCN2, which in turn led to ERK activation [16].

Moreover, the inhibition of GCN2, when combined with asparagine depletion through treatments like ASNase, activates the MAPK pathways. This dual mechanism of action induces cell death by triggering both apoptotic and cell survival signals, illustrating a therapeutic potential in leveraging these pathways [48]. In non-small cell lung cancer (NSCLC) cells, deprivation of specific amino acids such as glutamine, arginine, methionine, and lysine activates the AKT pathway through the GCN2/ATF4/REDD1 axis. This leads to the subsequent activation of mTORC2, which promotes a cell survival signal under amino acid scarcity [49]. This complex interplay between GCN2 and other signaling pathways accentuates the intricacy of cellular responses to amino acid limitation and underscores the pivotal role of GCN2 in maintaining cellular homeostasis and adapting to metabolic stress.

Other mechanisms

GCN2′s role in modulating the cellular response to interferons (IFNs) highlights its contribution to the complex interplay between cellular stress responses and tumor immune evasion. Specifically, in melanoma cells under amino acid deficiency, GCN2 mediates the downregulation of IFNAR1, a key receptor for Type 1 IFNs. This mechanism potentially enables tumors to circumvent the anti-tumorigenic effects of endogenous IFNs, suggesting a pathway that could be targeted therapeutically to enhance IFN responsiveness and combat immune evasion [50]. Additionally, GCN2’s role extends into metabolic regulation, as evidenced by its interaction with ethylmalonic encephalopathy protein 1, which is significant in the metastasis of triple-negative breast cancer. This interaction leads to the activation of the GCN2-EIF2α-ATF4 pathway, implicating GCN2 in the regulation of tumor metastasis and offering a novel perspective on targeting metabolic pathways in cancer treatment [51].

GCN2 plays a crucial role in protecting cancer cells by modulating various cellular processes. It responds to environmental stress and amino acid scarcity, maintaining cellular homeostasis through mechanisms such as regulation of protein synthesis and promotion of autophagy. GCN2′s involvement in key processes like angiogenesis, mitochondrial quality control, and ribosome biogenesis underscores its pivotal role in supporting tumor growth and resistance to therapy. Understanding GCN2’s multifaceted role in cancer biology could pave the way for new therapeutic strategies, potentially leading to more effective treatments for various cancers.

GCN2 in drug resistance

GCN2 plays a critical role in cellular adaptation to stress conditions, such as amino acid deprivation and oxidative damage, by regulating key genes like ASNS [52] and xCT [40,53]. This regulation allows cells to survive in challenging environments, potentially leading to drug resistance. Specifically, GCN2 reduces protein synthesis, preventing the accumulation of misfolded proteins and thereby reducing proteotoxic stress. Additionally, GCN2 induces the expression of the 19S subunit of the proteasome, enhancing the cell's capability to degrade damaged proteins. This mechanism contributes to resistance against proteasome inhibitors [54,55], highlighting its significance in the cellular stress response (Fig. 2).Fig. 2 Mechanisms of GCN2-mediated drug resistance. The GCN2-ATF4 axis mediates the expression of the ASNS gene, forming a crucial resistance mechanism against ASNase. In the presence of cisplatin, which increases cellular ROS levels, resistance is facilitated by the SLC7A11 transporter, also regulated by the GCN-ATF4 axis, that helps in overcoming oxidative stress. In treatments involving proteasome inhibitors (PIs), GCN2 alleviates amino acid scarcity by reducing protein synthesis while concurrently inhibiting the upregulation of the 19S subunit, contributing to PI resistance. Additionally, the GCN2-ATF4 axis enhances the expression of autophagy-related genes such as ATG3, ATG5, ATG12, and LC3B, helping cells evade apoptosis induced by HAP70 inhibitors. Apatinib's inhibition of the GLS1 gene leads to glutamine deficiency in cells, which activates the GCN2-ATF4 axis, resulting in the upregulation of SLC1A5 and ASNS to compensate for glutamine shortages. Furthermore, GCN2 inhibits JNK-mediated apoptosis, promoting resistance to various chemotherapeutic agents including epirubicin, paclitaxel, vemurafenib, and FGFR1 inhibitors, showcasing its broad impact on drug resistance.

Fig. 2

L-asparaginase (ASNase)

The exploration of amino acid metabolism as a therapeutic strategy has revealed promising avenues for developing innovative cancer treatments. At the forefront of this approach is ASNase, which plays a crucial role in managing acute lymphoblastic leukemia (ALL) by depleting asparagine [56]. The effectiveness of ASNase is significantly enhanced or diminished by the modulation of asparagine synthetase (ASNS) expression, which is regulated through the GCN2/ATF4 pathway, highlighting a crucial target for intervention [52]. GCN2 inhibition has shown potential to increase the sensitivity of cancer cells to ASNase, especially in those cells with low baseline levels of ASNS, demonstrating efficacy both in laboratory and clinical settings(48). MYC, a known contributor to cancer metabolism, activates GCN2 kinase, leading to increased ASNS expression and subsequently contributing to ASNase resistance in ALL [18]. Additionally, the inhibition of Bruton's tyrosine kinase, either genetically or pharmacologically with agents like ibrutinib, can disrupt c-Myc function. This disruption reduces the production of uncharged tRNAs and diminishes the activation of the GCN2-ATF4-ASNS pathway, showing significant potential to improve treatment outcomes across various ALL genomic subtypes.

In the context of acute myeloid leukemia (AML), sensitivity to asparagine depletion is notably less compared to ALL, largely due to differential ASNS expression [57].While ASNase holds potential for AML therapy, particularly in combination with methotrexate or high-dose cytarabine, its efficacy generally falls short of what is observed in ALL [58,59]. However, combining ASNase with GCN2 inhibitors has been shown to lower the IC50 values for ASNase in AML cells, suggesting that GCN2 plays a key role in the resistance mechanism to ASNase in AML. This combination approach also showed similar reductions in IC50 values in pancreatic cancer cells [48].

Furthermore, the pharmacological inhibition of the ASNS gene, for instance, with Bisabosqual A (Bis A), has been shown to synergistically enhance the therapeutic potential of ASNase against non-small cell lung cancer (NSCLC). However, this may activate the GCN2-ASNS pathway, indicating potential negative feedback mechanisms at play [60]. This complex interplay between ASNase, GCN2 inhibition, and ASNS expression underscores the nuanced dynamics of amino acid metabolism in cancer therapy, offering a rich landscape for the development of more effective treatments.

Chemotherapeutic agents

Enhanced synthesis of glutathione (GSH), a major intracellular antioxidant, is a common adaptation among cisplatin-resistant tumor cells, posing a significant challenge to the efficacy of cisplatin-based chemotherapy. In gastric cancer, resistance is often associated with elevated expression of SLC7A11 (xCT), a critical enzyme in GSH synthesis. This enzyme is upregulated via the GCN2 pathway, serving to counteract the cytotoxic effects of cisplatin and promote detoxification processes(40, 53). Moreover, Growth Differentiation Factor 15 (GDF15) plays a pivotal role in cisplatin resistance. It is markedly overexpressed in resistant cells and activates the GFRAL-GCN2-eIF2α-ATF4-xCT signaling pathway, which leads to increased intracellular production of GSH. This upsurge in GSH levels effectively neutralizes the cytotoxic impact of cisplatin, enabling cancer cells to thrive despite the presence of the drug [40,61].

In the context of breast cancer, cells that are resistant to other chemotherapeutic agents such as epirubicin or paclitaxel show a similar reliance on the GCN2 pathway for survival. Silencing GCN2 in these cells significantly reduces their clonogenic capacity, which is associated with the upregulation of JNK and PERK expression and activity. This regulatory change is linked to increased expression of FOXO3, a transcription factor that plays a crucial role in cellular stress responses and apoptosis [62].

Proteasome inhibitors

The sensitivity of multiple myeloma (MM) cells to proteasome inhibitors (PIs) is primarily due to their role in disrupting the breakdown of toxic misfolded proteins, which accumulate because of high-level immunoglobulin production inherent to this cancer type [63]. In the treatment of MM, PIs are notably effective at initiating endoplasmic reticulum (ER) stress and subsequent apoptotic signaling pathways [64]. However, the effectiveness of PIs can be compromised by the concurrent activation of a GCN2-dependent amino acid response (AAR) in MM cells [55]. This response may potentially foster resistance to PIs, as it helps cells adapt to the induced amino acid scarcity. Additionally, PI resistance in MM has been correlated with reduced expression of 19S proteasome subunits [54]. Observations of decreased mRNA levels for several 19S subunits in cells recovering from PI treatment might indicate the early stages of resistance development, or possibly reflect the presence of cells that inherently exhibit lower 19S subunit expression before treatment begins [54,55]. Furthermore, inhibiting GCN2 markedly enhances the expression levels of 19S subunits in recovering cells, suggesting a potential association between GCN2 inhibition and the expression of these subunits, thereby possibly impacting PI resistance mechanisms in MM cells.

Small molecules

In breast cancer, the overexpression of Hsp70 is a common adaptation that enables cells to manage misfolded proteins that would otherwise lead to apoptosis or significant dysfunction in normal cells [15]. GCN2 is pivotal in the resistance of breast cancer cells to Hsp70 inhibitors (MAL3–101), with its inhibition significantly reducing the survival of resistant cells. This suggests that breast cancer cells rely on GCN2- induced autophagy as a survival mechanism, particularly when proteostasis is challenged by Hsp70 inhibition, showcasing a sophisticated adaptive strategy [15]. In the context of melanoma and colorectal cancer cells harboring the BRAF mutation, short-term treatment with BRAF kinase inhibitors, such as vemurafenib, leads to the activation of the GCN2 kinase. This activation induces ATF4, a critical factor that may enhance cell survival in the face of BRAF inhibition, illustrating how cancer cells adapt to targeted therapies [65].

Further, in human non-small cell lung cancer (NSCLC) cells, Apatinib, a tyrosine kinase inhibitor targeting VEGFR-2, disrupts glutamine metabolism. It achieves this by inhibiting GLS1 and activating the amino acid response (AAR) pathway through GCN2/eIF2α/ATF4. This leads to overexpression of ATF4, which increases the expression of SLC1A5 and ASNS, promoting glutamine consumption and metabolization, another example of adaptive metabolic reprogramming in response to therapy [66]. Additionally, GCN2 plays a significant role in drug resistance to treatments such as fibroblast growth factor receptor 1 (FGFR1) inhibitors. In T-ALL cells, resistance to FGFR1 inhibitors arises from the activated GCN2-ATF4 pathway, which sustains mTORC1 activation, contributing to ongoing drug resistance [67].

These insights into the modulation of amino acid metabolism and stress response pathways, particularly through the GCN2 kinase, are crucial in understanding the efficacy and resistance mechanisms of various cancer treatments. The activation of GCN2 and its downstream effects on ATF4 expression and nutrient transporter regulation are central to the cellular response to these therapies. Targeting these pathways offers promising strategies for enhancing the effectiveness of cancer treatments and overcoming drug resistance, underscoring the importance of continued research in this area to improve patient outcomes across a broad spectrum of malignancies.

GCN2 induced cell death

GCN2 does not always serve as a protective mechanism for cell survival. In certain scenarios, such as when the stress response to amino acid deprivation (leucine, cystine, or glutamine) becomes uncontrolled, it can initiate pathways leading to programmed cell death [21,[68], [69], [70]] (Fig. 3). This underlines the complex roles of GCN2 in cancer biology and emphasizes the importance of GCN2-mediated mechanisms in enhancing the efficacy of specific pharmacological agents.Fig. 3 Mechanisms of apoptosis modulated by GCN2. GCN2 triggers programmed cell death through the GCN2-ATF4-CHOP pathway when nutrient deprivation is irreversible, a process also implicated in some drug-induced cell deaths. Additionally, deprivation of leucine activates the GCN2 pathway, which represses Sterol Regulatory Element-Binding Protein 1C (SREBP1C) and impacts the expression of Fatty Acid Synthase (FASN), essential for lipid biosynthesis and critical in cancer cell growth. Deprivation of cystine elevates CHAC1 gene expression via the GCN2-ATF4 axis, leading to glutathione (GSH) degradation, which intensifies oxidative stress and results in cell death. Lack of glutamine increases susceptibility to TRAIL-induced apoptosis by upregulating TRAIL receptor 2 (TRAIL-R2) through the GCN2-ATF4 pathway, triggering apoptosis when these cells encounter TRAIL. Certain pharmacological agents such as cortisone activate GCN2, fostering the formation of stress granules (SGs) and inducing cell death. Methotrexate (MTX) stimulates GCN2, enhancing HMGB1 expression, whose release into the extracellular space can initiate immunogenic cell death (ICD). Furthermore, MTX and doxorubicin (DOXO) promote CALR gene expression through the GCN2-ATF4 pathway, increasing levels of calreticulin (CRT). CRT's translocation to the cell surface serves as an "eat me" signal, enabling ICD. This intricate interaction of GCN2 with cellular stress responses highlights its potential as a therapeutic target in cancer treatment.

Fig. 3

In A549/8 lung carcinoma cells, reduced glutamine levels disrupt cell cycle distribution and significantly induce apoptosis/necrosis. This effect is driven by a GCN2/eIF2α-dependent mechanism that increases CHOP and GADD34 mRNA expression, highlighting glutamine's critical role in cell survival and the severe impact of its deprivation [21]. Similarly, glutamine deprivation in TNBC cells increases their susceptibility to TRAIL-induced apoptosis, linked to the upregulation of TRAIL receptor 2 (TRAIL-R2/DR5) and the downregulation of FLICE-inhibitory protein (FLIP), with GCN2 kinase activation playing a role in this regulatory mechanism [68].

In breast cancer cells, the absence of leucine markedly reduces cell viability and proliferation and induces apoptosis. This process is regulated by the GCN2 pathway, which influences the expression of Fatty Acid Synthase (FASN) by repressing Sterol Regulatory Element-Binding Protein 1C (SREBP1C), crucial in lipid biosynthesis and cancer cell growth [69]. In triple-negative breast cancer (TNBC) cells, cystine deprivation activates the GCN2-eIF2α-ATF4 signaling cascade, leading to increased CHAC1 expression. The degradation of glutathione (GSH) by CHAC1 heightens oxidative stress, leading to cell death through mechanisms such as necroptosis and ferroptosis, underscoring TNBC cells' vulnerability to cystine deficits and oxidative damage(70).

Apoptosis modulated by GCN2 is crucial for the action of specific drugs, with ATF4-mediated gene transcription being a common pathway. The GCN2-ATF4-CHOP axis is central to apoptosis induced by agents such as borrelidin [71], pegylated-human-arginase I [72], proline-competitive phosphoribosylpyrophosphate synthetase inhibitors [73], and Na+/K+ATPase ligands [74], which ultimately lead to cell death. Moreover, drugs like methotrexate (MTX) [75,76] and doxorubicin [75] have been shown to induce apoptosis in melanoma and prostate cancer cells by exploiting the eIF2α phosphorylation pathway via GCN2 and PERK. This induction not only compromises cancer cell survival but also triggers an immunogenic response, potentially enhancing therapeutic efficacy by activating the immune system against tumor cells. This involves GCN2 activation, facilitating the translocation of calreticulin (CRT), an endoplasmic reticulum resident protein, to the cell surface [75,76], and the extracellular release of the high mobility group box-1 (HMGB1) protein [76], key events in initiating immunogenic cell death (ICD) in melanoma and prostate cancers. Additionally, MTX treatment leads to the activation of dendritic cells in mice, which is diminished when GCN2 is silenced [76].

Cytoplasmic stress granules (SGs) are non-membrane-bound cellular aggregates that form under various stress conditions, including those induced by vinca alkaloids such as vinorelbine (VRB). In U2OS cells, cortisone increases VRB-induced cell death and reduces the population of cells trapped in mitotic catastrophe, mediated by the core SG proteins G3BP1 and G3BP2. Cortisone affects SG dynamics and the integrated stress response (ISR) signal transduction pathways, ultimately influencing cell viability and death via GCN2 [77].

Chronic activation of the ISR can lead to apoptosis, suggesting that sustained activation of the GCN2 pathway might also inhibit tumor growth [78]. HC-7366, a novel orally bioavailable activator of GCN2 kinase, has demonstrated efficacy in this regard. HC-7366 monotherapy showed significant tumor growth inhibition in preclinical cancer models, including colorectal (78–95 % inhibition), head and neck (33 % regression), sarcoma (80 % inhibition), prostate (65 % inhibition), fibrosarcoma (84 % inhibition), and acute myeloid leukemia (98 % inhibition) [79,80].

HC-7366 treatment activated the ISR in tumors from treated mice, as evidenced by the induction of ATF4 target genes such as ASNS, PSAT1, and JUN [80]. Additionally, the treatment promoted the expression of the proapoptotic protein PUMA and led to a reduction in the levels of HIF1α and HIF2α. Metabolomic analysis of tumors treated with HC-7366 revealed significant changes in several metabolites associated with amino acid metabolism, oxidative stress, the urea cycle, and pyrimidine biosynthesis, indicating a broad metabolic impact on tumor cells [80].

In breast cancer models, HC-7366 has shown consistent anti-metastatic efficacy, reducing lung metastases by approximately 75 % across various studies. This anti-tumor effect is associated with a significant decrease in Ly6G+ polymorphonuclear myeloid-derived suppressor cells in the lungs, spleen, and blood, suggesting that HC-7366 may exert its anti-metastatic effects through modulation of the tumor immune microenvironment [81].These findings indicate that activating the GCN2 pathway with HC-7366 could be an effective strategy for cancer therapy.

In summary, the exploration of GCN2′s role in cancer therapy reveals a complex interplay between cellular stress responses and tumor cell viability. Modulating GCN2 and related pathways offers a multifaceted approach to cancer treatment, from direct induction of apoptosis to enhancement of immunogenic responses. As research progresses, the development of targeted therapies exploiting GCN2′s unique role in cellular stress responses holds promise for advancing cancer treatment strategies, highlighting the need for ongoing investigation into these mechanisms.

Role of GCN2 in pan-cancer

GCN2 is increasingly recognized for its potential in clinical applications, particularly in the treatment of various cancers such as papillary renal cell carcinoma (PRCC), head and neck Squamous cell carcinoma (HNSCC), and pancreatic ductal adenocarcinoma (PDAC) [[82], [83], [84]]. In PRCC, high GCN2 expression correlates with aggressive disease features, including larger tumor sizes, advanced TNM stages, high Fuhrman grades, and lymph node metastasis. This overexpression establishes GCN2 as a critical prognostic marker, associated with lower overall and progression-free survival rates [82]. Studies also show a significant prevalence of GCN2 in HNSCC, where most tumors exhibit moderate to strong expression levels, underscoring its role in tumor biology [83]. Further research into PDAC has identified a subtype with constitutive GCN2 activation, enhancing ATF4 signaling and increasing asparagine production. This suggests a novel metabolic dependency where exogenous asparagine might conserve aspartate reserves under stress, highlighting GCN2 inhibitors as promising therapeutic avenues [84].

Analysis of the TCGA dataset reveals high GCN2 expression in tumor tissues across 13 cancer types. To address the lack of normal adjacent tissue samples in some cancers, we merged GTEx normal tissue data with TCGA data. This merged dataset included 29 cancer types, with GCN2 expression notably high in 26 of these, indicating its significant role in tumor pathogenesis (Fig. 4A). In the TCGA dataset, high GCN2 expression correlates with poor prognosis in KIRC but with better prognosis in LGG and MESO (Fig. 4B). Additional analysis using the GEO database revealed that high GCN2 expression is associated with poor prognosis in AML, colon cancer, and pancreatic cancer, but with better prognosis in lung cancer, MM, and ovarian cancer, suggesting that GCN2′s impact on prognosis varies by tumor type (Fig. 4C).Fig. 4 GCN2 Pan-Cancer Analysis. GCN2 shows high expression in 13 cancer types according to the TCGA database. A combined analysis with the GTEx database indicates that GCN2 is highly expressed in 26 out of 29 cancer types (A). Within the TCGA dataset, high GCN2 expression correlates with poor prognosis in kidney renal clear cell carcinoma (KIRC) but predicts better outcomes in brain lower grade glioma (LGG) and mesothelioma (MESO) (B). Further studies using the GEO database demonstrate that elevated GCN2 levels are associated with poorer prognosis in acute myeloid leukemia (AML), colon cancer, and pancreatic cancer, while they are linked to better prognosis in lung cancer, multiple myeloma (MM), and ovarian cancer, highlighting the variable impact of GCN2 across different tumor types (C). Analysis of immune cell infiltration across 33 cancer types reveals that in certain cancers, GCN2 is positively correlated with immunosuppressive cells such as Tregs (D). Additionally, in the analysis of immune checkpoints, GCN2 expression consistently shows positive correlations with the expression of most immune checkpoints (E). For a detailed methodology of the pan-cancer analysis, please refer to Appendix 1. Cancer types: Adrenocortical Carcinoma (ACC), Bladder Urothelial Carcinoma (BLCA), Breast Invasive Carcinoma (BRCA), Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC), Cholangiocarcinoma (CHOL), Colon Adenocarcinoma (COAD), Diffuse Large B-Cell Lymphoma (DLBC), Esophageal Carcinoma (ESCA), Glioblastoma Multiforme (GBM), Head and Neck Squamous Cell Carcinoma (HNSC), Kidney Chromophobe (KICH), Kidney Renal Clear Cell Carcinoma (KIRC), and others. Key immune checkpoint-related transcripts: Sialic Acid Binding Ig Like Lectin 15 (SIGLEC15), Indoleamine 2,3-Dioxygenase 1 (IDO1), Cluster of Differentiation 274 also known as PD-L1 (CD274), Hepatitis A Virus Cellular Receptor 2 also known as TIM-3 (HAVCR2), Programmed Cell Death Protein 1 also known as PD-1 (PDCD1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), Lymphocyte Activation Gene 3 (LAG3), and Programmed Cell Death 1 Ligand 2 also known as PD-L2 (PDCD1LG2).

Fig. 4

Further analysis revealed a negative correlation between GCN2 and various immune cells in 33 cancer types, including T cell NK, T cell CD4+ central memory, T cell CD4+ effector memory, T cell CD4+ Th1, and B cell plasma. In some cancers, GCN2 positively correlates with immunosuppressive cells such as Tregs (Fig. 4D). This correlation may stem from GCN2′s role in sensing amino acid deprivation, such as tryptophan depletion—a common feature in the tumor microenvironment. This depletion can trigger a cellular stress response, leading to G1 phase cell cycle arrest in T cells, mediated by GCN2 activation. Thus, GCN2 may contribute to the immunosuppressive environment in tumors by impairing the proliferation and function of effector T cells while potentially favoring Treg expansion [85].

However, it is important to highlight that the effects of GCN2 on the tumor immune microenvironment remain controversial. T cells lacking GCN2 exhibit proliferation defects during activation [86], and CD8+ T cells devoid of GCN2 display impaired anti-tumor immunity in a murine glioma model [87]. Interestingly, activating effector CD8+ T cells with the GCN2 agonist halofuginone (halo) in vitro enhances their amino acid starvation response, oxidative metabolism, and effector functions. Mechanistically, autophagy and the CD98-mTOR signaling axis are critical downstream mediators of the phenotypes induced by halo treatment. The adoptive transfer of halo-treated CD8+ T cells into tumor-bearing mice leads to robust tumor control and curative responses. In vivo, halo-treated T cells, in conjunction with agonistic 4–1BB antibodies, suppress tumor growth in immune therapy-resistant mouse models. Crucially, treating human CD8+ T cells with halo also results in similar metabolic and functional reprogramming [88]. In immune checkpoint analysis, GCN2 expression correlated positively with the expression of most immune checkpoints (Fig. 4E). For instance, in LAML, patients with high GCN2 expression generally showed high expression of CD274, HAVCR2, PDCD1LG2, and SIGLEC15. In COAD patients, CD274, CTLA4, HAVCR2, PDCD1LG2, and TIGIT were positively correlated with GCN2. In PAAD, all immune checkpoints except SIGLEC15 were positively correlated with GCN2. These findings suggest that GCN2 plays a significant role in the tumor immune microenvironment and may influence responses to certain immunotherapies.

GCN2 inhibitors

Recent advancements in cancer therapy have emphasized the potential of various GCN2 inhibitors (Table 1), particularly Triazolo[4,5-d] pyrimidines (TAP), for their potent efficacy in targeting GCN2 within cancer cells. Notable compounds such as GCN2-IN-1 (A-92) [24,46,77,[89], [90], [91], [92], [93]], TAP20 [94,95], GCN2iA(48), GCN22iB [10,12,48,55,96,97] and Compounds 1 and 2 [98] have demonstrated significant inhibition of GCN2, marking a pivotal development in targeted cancer treatment strategies. Additional inhibitors include GCN2-IN-6 [14,99,100], a sulfonamide derivative, and broad-spectrum effects observed with small molecule drugs like GZD824 [101], further expanding the arsenal against cancer through diverse mechanisms of action.Table 1 Results of In Vivo and In Vitro Preclinical Studies on GCN2 Inhibitors.

Table 1Drug	Chemical structure	IC50 in Enzyme assay	IC50 in cell assay	IC50 of other targets	In vitro experiments	In vivo experiments	Ref	
Cell line	concentration	Main observation	Special	Mouse model	Dosage	Main observation	Special	
TAP20 (A245)	Image, table 1	17 nm	0.29–0.56um	GSK3α IC50 at 1.7 nm; GSK3β IC50 at 12 nm; CDK9/cyclinD1 IC50 at 180nm	143B/HCC1806	3um	Reduced the proliferation of ASCT2 KO HCC1806 cells when combined with concurrent silencing of SNAT1 or LAT1.	N.A	N.A	N.A	N.A	N.A	94	
MDA-MB-231/MDA-MB-468/HPAFII/SKOV3/OVCAR3	>1 µM	Suppressed GCN2.	N.A	N.A	N.A	N.A	N.A	95	
143B	1–3um	Dramatically reduced matrix-dependent invasion.	N.A	N.A	N.A	N.A	N.A	95	
MB-231/HPAF-II	3um	Inhibitors of proteostasis, MEK–ERK pathway, pan-CDK inhibitors, flavopiridol, and seliciclib, were potently
synergistic with TAP20.	N.A	N.A	N.A	N.A	N.A	95	
AST-0513	Image, table 1	15nm	N.A	N.A	SNU-1041	2 μM	Induced cell cycle arrest and apoptosis under amino acid deprivation conditions.	N.A	Mice	N.A	Adverse
effects on organs were not observed in mice.	N.A	83	
Detroit-562/FaDu/SNU-1041/SNU-1066/SNU-1076	1um	Inhibits the GCN2-ATF4 pathway, significant anti-proliferation effect.	N.A	N.A	N.A	N.A	N.A	83	
GCN2-IN-1	Image, table 1	<0.3um	0.3–3um	N.A	Hela	0.63–10μM	Effectively suppressed GCN2 activity, led to a decrease in basal eIF2α phosphorylation levels.	At low concentrations ranging from 0 to 0.31 μM, there is a paradoxical increase in GCN2 phosphorylation without noticeable activation of downstream signaling pathways. At concentrations between 10 and 40 μM, a dose-dependent increase in eIF2α phosphorylation was observed, which was associated with the activation of PERK kinase.	N.A	N.A	N.A	N.A	89	
Mic60-low PC3	10um	Inhibited proliferation and induced Annexin V-associated apoptosis and caspase-dependent cell death, particularly in Mic60-silenced PC3 cells compared to control cultures.	N.A	N.A	N.A	N.A	N.A	24	
U20s	4um	Blocked the assembly of SGs induced by mRNA transfection.	N.A	N.A	N.A	N.A	N.A	90	
U20S	4um	Blocked the assembly of SGs induced by Cortisone.	N.A	N.A	N.A	N.A	N.A	77	
HeLa	2um	Disrupts the timing and phosphorylation levels of crucial mitotic regulators, leading to improper chromosome alignment, chromosome missegregation, an increased incidence of tripolar spindles, and delayed mitotic progression. This effect is significantly enhanced when combined with Aurora A inhibition, resulting in exacerbated mitotic abnormalities and increased cell death.	N.A	N.A	N.A	N.A	N.A	46	
A549	10um	Simultaneous use PERK inhibitor rescued the negative effect of CuET on translation.	N.A	N.A	N.A	N.A	N.A	93	
MDA-MB 231	1um	Reduced mutp53 protein levels.	N.A	N.A	N.A	N.A	N.A	91	
GCN2-IN-6	Image, table 1	1.8nm	9.3nm	PERK IC50 at 230nm	CCRF-CEM	9.3um	Antiproliferative activity in combination with asparaginase.	N.A	CCRF-CEM ALL xenograft model	3 mg kg-1	Suppression of GCN2 pathway activation with asparaginase treatment.	N.A	99	
OCI-LY	7.5um	Inhibited cell proliferations, combined treatment with SIRT3 inhibitor (YC8–02) yielded significantly greater anti-lymphoma effect.	N.A	N.A	N.A	N.A	N.A	100	
Karpas	10um	Inhibited cell proliferations, combined treatment with SIRT3 inhibitor (YC8–02) yielded significantly greater anti-lymphoma effect.	N.A	N.A	N.A	N.A	N.A	100	
Hela	0.5um	Reverse the SLC7A11 expression induced by KYN hinders cystine uptake.	N.A	N.A	N.A	N.A	N.A	14	
Triazolo[4,5-d]pyrimidine derivatives Compound 1	Image, table 1	47.6nm	N.A	PKR IC50 at 119.3nm	National Cancer Institute NCI-60 Tumor Cell Screening Program	10um	Both 1 and 2 displayed cytotoxic activity
against cells within the different types of cancers tested. Leukemia and breast cancer cell lines comprised
the only cancer groups that were uniformly sensitive to both 1 and 2,
with the greatest sensitivity seen in the leukemia SR cell line.	N.A	N.A	N.A	N.A	N.A	98	
Triazolo[4,5-d]pyrimidine derivatives Compound 2	Image, table 1	18.6nm	N.A	PKR IC50 at 39.9nm	National Cancer Institute NCI-60 Tumor Cell Screening Program	10um	N.A	N.A	N.A	N.A	N.A	98	
GCN2iA	Image, table 1	4nm	N.A	GSK3β>75 % inhibition at 1um	U20S	1um	Suppressed GCN2 and eIF2α phosphorylation along with ATF4 expression in amino acid-deficient conditions.	Unfavorable pharmacokinetic profile in vivo.	N.A	N.A	N.A	N.A	97	
CCRF-CEM/MOLT-4/SU86.86/AsPC-1	1um	Enhance sensitivity to ASNase.	N.A	N.A	N.A	N.A	N.A	97	
GCN2iB	Image, table 1	2.4nm	N.A	MAP2K5/STK10/ZAK >95 % inhibition at 1μmol/L	CCRF-CEM/MV-4–11/SU.86.86	1um	Combined treatment with ASNase showed antiproliferative effect.	In the absence of external stress, low concentrations (10–100 nm) have the potential to activate GCN2.	CCRF-CEM ALL xenograft model	10 mg kg-1 twice daily	Cotreated with ASNase suppressed GCN2 pathway, elicited potent antitumor
activity.	No weight loss	97	
LNCaP/C4–2B/22Rv1/PC-3	500 nM to 10µM	Significantly impeded the proliferation.	N.A	MV-4–11 and SU.86.86 xenografts	10 mg kg-1 twice daily	Robust antitumor activity of the combination of GCN2iB and ASNase.	SU.86.86 model showed a modest cachectic body weight reduction	97	
LNCaP/C4–2B/22Rv1/PC-3	2um	Decreased the expression of SLC genes, led to a reduction in GCN2 activation.	N.A	Disseminated ALL
xenograft model (MOLT-3).	10 mg kg-1 twice daily	The combination of ASNase and GCN2 inhibitor (GCN2iB) provided a survival advantage compared to the vehicle-treated control.	No weight loss	97	
Clone cell line from pancreatic tumors from KPC mice with constitutively active GCN2 metabolic	1/2/5 um	Sufficient to reduce the expression of ATF4. Inhibiting the proliferation of a sensitive clone that acquires oligomycin resistance from co-culturing with a resistant clone.	N.A	Cancer cell (LNCaP/22Rv1)/ patient derived androgen-sensitive tumor xenograft models	30 mg kg-1 twice daily for durations between 2 and 6 weeks	Pronounced anti-tumor efficacy across all four models.	No weight loss	12	
HCC	1um	Increased EdU incorporation, reduced accumulation of p21, decreased expression of SLC7A1, lowered SESTRIN2/SESN2 mRNA and protein levels, activated mTORC1, and enhanced autophagy.	N.A	Subcutaneous SNU-398 xenograft tumors in mice	10 mg kg-1	
Combined treatment with arginine deprivation induced the expression of BCL2 and SASP-associated genes, as well as β-galactosidase staining in xenograft tumors. Additionally, when used in conjunction with ABT-263, this treatment significantly reduced tumor growth in arginine-restricted mice, specifically in the SNU-398 tumor model.	No weight loss	12	
HCC/ PC-3/SKLMS/MDA-MB-231	1um	Combined treatment of Arg-deprivation with GCN2iB and the pan-BCL2 inhibitor ABT-263 significantly increased the number of apoptotic cells.	N.A	Hepa55.1c subcutaneous xenografts	10 mg kg-1	Combined
with ABT-263 further decreased tumor growth in Arg restricted mice.	No weight loss	84	
HT-1080	1um	Reverse CHAC1 induction and the corresponding cell death in response to cystine deprivation.	N.A	HepaMP-9–1/SNU-398 xenografts	10 mg kg-1	Combined Arg deprivation harboring tumors and also developed senescent cells.	No weight loss	10	
RPMI-
8226/OPM2/
NCI-H929	1um	Enhanced the carfilzomib-induced reduction on day7.	N.A	HepaMP-9–1 xenografts	10 mg kg-1	Increased levels of VEGF.	No weight loss	55	
RPMI-8226	1um	After CFZ treatment on day 5, deregulated DDIT3,
ATF3, CHAC1, SESN2, SLC7A11, and TRIB. Increased 20S and particularly 19S proteasome-subunit
transcript levels.	N.A	N.A	N.A	N.A	N.A	55	
GZD824	Image, table 1	0.3–1uM	N.A	BCR/ABL IC50 at 0.34 nM	HT-1080	2um	Prevented ATF4 induction and phosphorylation of
GCN2 at T899 during
halofuginone stress.	At low concentrations (approximately 0.1 μM), GZD824 induces eIF2α phosphorylation and ATF4 expression in a GCN2-dependent manner under normal nutrient conditions. However, at higher concentrations (0.3–1 μM), GZD824 inhibits ATF4 induction even under GCN2-activating stress conditions.	N.A	N.A	N.A	N.A	101	

Interestingly, some drugs exhibit different effects on GCN2 at varying concentrations. For example, at low concentrations, GCN2iB can paradoxically activate GCN2, enhancing the phosphorylation of eIF2 and ATF4 expression in HEK293 cells, illustrating its potential as a nuanced therapeutic agent for modulating stress responses [48]. Similarly, GCN2-IN-1 exhibits a dual action in HeLa cells, where it paradoxically increases GCN2 phosphorylation at low doses without affecting downstream signals, while higher doses suppress GCN2, reducing eIF2α phosphorylation and further activating PERK kinase to trigger the ISR [89]. Extensive research on GCN2 inhibitors has significantly advanced their potential in cancer therapy by elucidating their impact on cancer cell behavior and aiding in the development of targeted treatments. However, their clinical application is still evolving. Primarily designed for in vitro use, in vivo studies are limited to specific compounds like GCN2iB, AST-0513, and GCN2-IN-6. Issues regarding their specificity and potential off-target effects remain prominent. Although these inhibitors effectively block ISR under amino acid scarcity in vitro, their effect on GCN2′s role in cell proliferation is unclear. The promising prospects of combination therapies involving GCN2 inhibitors warrant further exploration.

Conclusion

GCN2 plays diverse roles in tumor cells depending on the context, primarily recognized for its protective functions in tumor cells under stress. While inhibiting GCN2 alone does not significantly impact tumor cell growth, its influence on downstream gene expressions has been linked to mechanisms of drug resistance across various cancers. This insight suggests that a combined approach targeting GCN2 could provide an effective strategy to counter drug resistance in cancer therapy.

Recent studies have further explored the pro-apoptotic pathways activated by GCN2, illuminating how this kinase might be harnessed to induce tumor cell death. Several clinical trials are currently investigating the activation of GCN2 through small molecule drugs such as HC-7366 (NCT06234605, NCT05121948, NCT06285890) and NXP800 (NCT05226507). HC-7366 is being tested in combination with Azacitidine and Venetoclax for treating AML and with Belzutifan for renal cell carcinoma. Meanwhile, NXP800 is under evaluation as a monotherapy for advanced ovarian cancer. In the field of immunotherapy, the role of GCN2 is drawing attention due to its significant impact on immune cell functions. Targeting GCN2 to boost the efficacy of immune cell therapies presents a promising path for advancing cancer treatment.

In conclusion, GCN2 is a multifaceted kinase responsive to cellular stress, influencing tumor progression, treatment resistance, and potentially leading to cell death under certain circumstances. Understanding its complex role in cancer biology is crucial for developing targeted therapeutic strategies that exploit its unique functions. Continued research into GCN2 could unlock new possibilities for cancer treatment, particularly in overcoming drug resistance and enhancing the efficacy of immunotherapies.

Funding

This study was funded by the Hangzhou municipal biomedical and health industry development support special science and technology project, with grant numbers 2021WJCY096 , 2021WJCY243 , 2021WJCY245 , and 2021WJCY246 .

CRediT authorship contribution statement

Can Chen: Writing – original draft, Validation, Conceptualization. Yaping Xie: Writing – original draft, Conceptualization. Shenxian Qian: Validation, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix Supplementary materials

Image, application 1

Acknowledgements

Not applicated.

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.tranon.2024.102096.
==== Refs
References

1 Vander Heiden M.G. DeBerardinis R.J. Understanding the intersections between metabolism and cancer biology Cell 168 4 2017 657 669 28187287
2 Costa-Mattioli M. Walter P. The integrated stress response: from mechanism to disease Science (1979) 368 6489 2020 eaat5314
3 Castilho B.A. Shanmugam R. Silva R.C. Ramesh R. Himme B.M. Sattlegger E Keeping the eIF2 alpha kinase Gcn2 in check Biochimica et Biophysica Acta (BBA)-Mol. Cell Res. 1843 9 2014 1948 1968
4 Lageix S. Zhang J. Rothenburg S. Hinnebusch A.G. Interaction between the tRNA-binding and C-terminal domains of Yeast Gcn2 regulates kinase activity in vivo PLoS Genet. 11 2 2015 e1004991
5 Baird T.D. Wek R.C. Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism Adv. Nutr. 3 3 2012 307 321 22585904
6 Dong J. Qiu H. Garcia-Barrio M. Anderson J. Hinnebusch A.G Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain Mol. Cell 6 2 2000 269 279 10983975
7 Xia X. Lei L. Qin W. Wang L. Zhang G. Hu J. GCN2 controls the cellular checkpoint: potential target for regulating inflammation Cell Death. Discov. 4 1 2018 20
8 Gold L.T. Masson G.R. GCN2: roles in tumour development and progression Biochem. Soc. Trans. 50 2 2022 737 745 35311890
9 Vynnytska-Myronovska B.O. Kurlishchuk Y. Chen O. Bobak Y. Dittfeld C. Huther M. Arginine starvation in colorectal carcinoma cells: sensing, impact on translation control and cell cycle distribution Exp. Cell Res. 341 1 2016 67 74 26751966
10 Missiaen R. Anderson N.M. Kim L.C. Nance B. Burrows M. Skuli N. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment Cell Metab. 34 8 2022 1151 -67.e7 35839757
11 Kardos G.R. Wastyk H.C. Robertson G.P. Disruption of proline synthesis in melanoma inhibits protein production mediated by the GCN2 pathway Mol. Cancer Res. 13 10 2015 1408 1420 26082174
12 Cordova R.A. Misra J. Amin P.H. Klunk A.J. Damayanti N.P. Carlson K.R. GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis Elife 2022 11
13 Broer A. Rahimi F. Broer S. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells J. Biol. Chem. 291 25 2016 13194 13205 27129276
14 Fiore A. Zeitler L. Russier M. Gross A. Hiller M.K. Parker J.L. Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling Mol. Cell 82 5 2022 920 -32.e7 35245456
15 Sannino S., Yates M.E., Schurdak M.E., Oesterreich S., Lee A.V., Wipf P., Brodsky J.L.J.E. Unique integrated stress response sensors regulate cancer cell susceptibility when Hsp70 activity is compromised. 2021;10:e64977.
16 Parzych K. Saavedra-García P. Valbuena G.N. Al-Sadah H.A. Robinson M.E. Penfold L. The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation Oncogene 38 17 2019 3216 3231 30626938
17 Adam I. Dewi D.L. Mooiweer J. Sadik A. Mohapatra S.R. Berdel B. Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation Oncoimmunology 7 12 2018 e1486353
18 Butler M. van Ingen Schenau D.S. Yu J. Jenni S. Dobay M.P. Hagelaar R. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway Blood J. Am. Soc. Hematol. 138 23 2021 2383 2395
19 Schmidt S. Gay D. Uthe F.W. Denk S. Paauwe M. Matthes N. A MYC-GCN2-eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer Nat. Cell Biol. 21 11 2019 1413 1424 31685988
20 Wang Y. Ning Y. Alam G.N. Jankowski B.M. Dong Z. Nor J.E. Polverini P.J. Amino acid deprivation promotes tumor angiogenesis through the GCN2/ATF4 pathway Neoplasia 15 8 2013 989 997 23908598
21 Drogat B. Bouchecareilh M. North S. Petibois C. Deleris G. Chevet E. Acute l-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells J. Cell Physiol. 212 2 2007 463 472 17348020
22 Matassa D.S. Amoroso M.R. Agliarulo I. Maddalena F. Sisinni L. Paladino S. Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1 Cell Death. Dis. 4 10 2013 e851 24113185
23 Pathria G. Scott D.A. Feng Y. Sang Lee J. Fujita Y. Zhang G. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival EMBO J. 37 20 2018
24 Ghosh J.C. Perego M. Agarwal E. Bertolini I. Wang Y. Goldman A.R. Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability Proc. Natl. Acad. Sci. USA 119 8 2022
25 Piecyk M. Triki M. Laval P.A. Duret C. Fauvre J. Cussonneau L. The stress sensor GCN2 differentially controls ribosome biogenesis in colon cancer according to the nutritional context Mol. Oncol. 2023
26 Nofal M. Wang T. Yang L. Jankowski C.S.R. Hsin-Jung Li S Han S. GCN2 adapts protein synthesis to scavenging-dependent growth Cell Syst. 13 2 2022 158 -72.e9 34706266
27 Ye J. Palm W. Peng M. King B. Lindsten T. Li M.O. GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2 Genes Dev. 29 22 2015 2331 2336 26543160
28 Chattopadhyay N. Berger A.J. Koenig E. Bannerman B. Garnsey J. Bernard H. KRAS genotype correlates with proteasome inhibitor ixazomib activity in preclinical in vivo models of colon and non-small cell lung cancer: potential role of tumor metabolism PLoS. One 10 12 2015 e0144825
29 Tameire F. Verginadis I.I. Leli N.M. Polte C. Conn C.S. Ojha R. ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression Nat. Cell Biol. 21 7 2019 889 899 31263264
30 Saxton R.A. Sabatini D.M. mTOR signaling in growth, metabolism, and disease Cell 168 6 2017 960 976 28283069
31 Kim J. Kundu M. Viollet B. Guan K.-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 Nat. Cell Biol. 13 2 2011 132 141 21258367
32 Munn D.H., Mellor ALJTii. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses. 2013;34(3):137–43.
33 Uyttenhove C. Pilotte L. Théate I. Stroobant V. Colau D. Parmentier N. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase Nat. Med. 9 10 2003 1269 1274 14502282
34 Tsai Y.C. Weissman A.M. The unfolded protein response, degradation from the endoplasmic reticulum, and cancer Genes. Cancer 1 7 2010 764 778 21331300
35 Marjon P.L. Bobrovnikova-Marjon E.V. Abcouwer S.F. Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress Mol. Cancer 3 1 2004 1 12 14723797
36 Martínez-Reyes I. Sánchez-Aragó M. Cuezva J.M. AMPK and GCN2–ATF4 signal the repression of mitochondria in colon cancer cells Biochem. J. 444 2 2012 249 259 22435535
37 Quirós P.M. Mottis A. Auwerx J. Mitonuclear communication in homeostasis and stress Nature Rev. Mol. Cell Biol. 17 4 2016 213 226 26956194
38 Hsu C.-C. Tseng L.M. Lee H.-C. Role of mitochondrial dysfunction in cancer progression Exp. Biol. Med. 241 12 2016 1281 1295
39 Gesualdi N.M. Chirico G. Pirozzi G. Costantino E. Landriscina M. Esposito F. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis Stress 10 4 2007 342 350 17853063
40 Wang S.-F. Chen M.-S. Chou Y.-C. Ueng Y.-F. Yin P.-H. Yeh T.-S. Lee H.-C. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway Oncotarget. 7 45 2016 74132 27708226
41 Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations J. Clin. Invest. 123 9 2013 3664 3671 23999440
42 Anderson R.G. Ghiraldeli L.P. Pardee T.S. Mitochondria in cancer metabolism, an organelle whose time has come? Biochimica et Biophysica Acta (BBA)-Rev. Cancer 1870 1 2018 96 102
43 Pavlova N.N. Thompson C.B. The emerging hallmarks of cancer metabolism Cell Metab. 23 1 2016 27 47 26771115
44 Hinnebusch A.G. Translational regulation of GCN4 and the general amino acid control of yeast Annu. Rev. Microbiol. 59 1 2005 407 450 16153175
45 Darnell A.M. Subramaniam A.R. O'Shea E.K. Translational control through differential ribosome pausing during amino acid limitation in mammalian cells Mol. Cell 71 2 2018 229 243 e11 30029003
46 Stonyte V. Mastrangelopoulou M. Timmer R. Lindbergsengen L. Vietri M. Campsteijn C. Grallert B. The GCN2/eIF2alphaK stress kinase regulates PP1 to ensure mitotic fidelity EMBo Rep. 24 8 2023 e56100 37291955
47 Thiaville M.M. Pan Y.-X. Gjymishka A. Zhong C. Kaufman R.J. Kilberg M.S. MEK signaling is required for phosphorylation of eIF2α following amino acid limitation of HepG2 human hepatoma cells J. Biol. Chem. 283 16 2008 10848 10857 18287093
48 Nakamura A. Nambu T. Ebara S. Hasegawa Y. Toyoshima K. Tsuchiya Y. Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response Proc. Natl. Acad. Sci. 115 33 2018 E7776 E7E85 30061420
49 Jin H.O. Hong S.E. Kim J.Y. Jang S.K. Park I.C Amino acid deprivation induces AKT activation by inducing GCN2/ATF4/REDD1 axis Cell Death. Dis. 12 12 2021 1127 34862383
50 Bhattacharya S. HuangFu W.C. Dong G. Qian J. Baker D.P. Karar J. Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses Oncogene 32 36 2013 4214 4221 23045272
51 Yang S.Y. Liao L. Hu S.Y. Deng L. Andriani L. Zhang T.M. ETHE1 accelerates triple-negative breast cancer metastasis by activating GCN2/eIF2alpha/ATF4 signaling Int. J. Mol. Sci. 24 19 2023
52 Broome J. Evidence that the l-asparaginase of guinea pig serum is responsible for its antilymphoma effects: II. Lymphoma 6C3HED cells cultured in a medium devoid of l-asparagine lose their susceptibility to the effects of guinea pig serum in vivo J. Exp. Med. 118 1 1963 121 148 14015822
53 Wang S.F. Chang Y.L. Fang W.L. Li A.F. Chen C.F. Yeh T.S. Growth differentiation factor 15 induces cisplatin resistance through upregulation of xCT expression and glutathione synthesis in gastric cancer Cancer Sci. 114 8 2023 3301 3317 37260027
54 Tsvetkov P. Sokol E. Jin D. Brune Z. Thiru P. Ghandi M. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers Proc. Natl. Acad. Sci. 114 2 2017 382 387 28028240
55 Saavedra-García P. Roman-Trufero M. Al-Sadah H.A. Blighe K. López-Jiménez E. Christoforou M. Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs Proc. Natl. Acad. Sci. 118 17 2021 e2018229118
56 Ali U. Naveed M. Ullah A. Ali K. Shah S.A. Fahad S. Mumtaz A.S. l-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): a novel approach to target ALL Eur. J. Pharmacol. 771 2016 199 210 26698391
57 Michelozzi I.M. Granata V. De Ponti G. Alberti G. Tomasoni C. Antolini L. Acute myeloid leukaemia niche regulates response to l-asparaginase Br. J. Haematol. 186 3 2019 420 430 31044436
58 Capizzi R.L. Davis R. Powell B. Cuttner J. Ellison R.R. Cooper M.R. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia–a cancer and Leukemia Group B Study J. Clin. Oncol. 6 3 1988 499 508 3162515
59 Hansen H. Canellos G. L-asparaginase treatment of acute myeloblastic leukemia Oncology. 24 5 1970 349 357 5275037
60 Pan Y. Suzuki T. Sakai K. Hirano Y. Ikeda H. Hattori A. Bisabosqual A: a novel asparagine synthetase inhibitor suppressing the proliferation and migration of human non-small cell lung cancer A549 cells Eur. J. Pharmacol. 960 2023 176156
61 Baek K.E. Yoon S.R. Kim J.-T. Kim K.S. Kang S.H. Yang Y. Upregulation and secretion of macrophage inhibitory cytokine-1 (MIC-1) in gastric cancers Clinica Chimica Acta 401 1–2 2009 128 133
62 Alasiri G. Jiramongkol Y. Trakansuebkul S. Ke H.L. Mahmud Z. Intuyod K. Lam E.W. Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival Mol. Cell Endocrinol. 515 2020 110932
63 Suraweera A. Münch C. Hanssum A. Bertolotti A. Failure of amino acid homeostasis causes cell death following proteasome inhibition Mol. Cell 48 2 2012 242 253 22959274
64 Saavedra-García P. Martini F. Auner H.W. Proteasome inhibition in multiple myeloma: lessons for other cancers Am. J. Physiol.-Cell Physiol. 318 3 2020 C451 CC62 31875696
65 Nagasawa I. Kunimasa K. Tsukahara S. Tomida A. BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib Biochem. Biophys. Res. Commun. 482 4 2017 1491 1497 27965097
66 Zhou X. Zhou R. Rao X. Hong J. Li Q. Jie X. Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer Cell Death. Dis. 13 7 2022 636 35864117
67 Z-j Zhang Q-f Wu A-q Ren Chen Q. J-z Shi J-p Li ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming Acta Pharmacol. Sin. 2023 1 14
68 Mauro-Lizcano M. Lopez-Rivas A. Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells Cell Death. Dis. 9 2 2018 205 29434187
69 Xiao F. Wang C. Yin H. Yu J. Chen S. Fang J. Guo F Leucine deprivation inhibits proliferation and induces apoptosis of human breast cancer cells via fatty acid synthase Oncotarget. 7 39 2016 63679 27579768
70 Chen M.-S. Wang S.-F. Hsu C.-Y. Yin P.-H. Yeh T.S. Lee H.C. Tseng L.M. CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2α-ATF4 pathway Oncotarget. 8 70 2017 114588
71 Sidhu A. Miller J.R. Tripathi A. Garshott D.M. Brownell A.L. Chiego D.J. Borrelidin induces the unfolded protein response in oral cancer cells and chop-dependent apoptosis ACS. Med. Chem. Lett. 6 11 2015 1122 1127 26617965
72 Morrow K. Hernandez C. Raber P. Del Valle L. Wilk A. Majumdar S. Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia Leukemia 27 3 2013 569 577 22926702
73 Arita T. Morimoto M. Yamamoto Y. Miyashita H. Kitazawa S. Hirayama T. Prolyl-tRNA synthetase inhibition promotes cell death in SK-MEL-2 cells through GCN2-ATF4 pathway activation Biochem. Biophys. Res. Commun. 488 4 2017 648 654 28087278
74 Wei C. Lin M. Jinjun B. Su F. Dan C. Yan C. Involvement of general control nonderepressible kinase 2 in cancer cell apoptosis by posttranslational mechanisms Mol. Biol. Cell 26 6 2015 1044 1057 25589675
75 Giglio P. Gagliardi M. Tumino N. Antunes F. Smaili S. Cotella D. PKR and GCN2 stress kinases promote an ER stress-independent eIF2alpha phosphorylation responsible for calreticulin exposure in melanoma cells Oncoimmunology 7 8 2018 e1466765
76 Li C. Sun H. Wei W. Liu Q. Wang Y. Zhang Y. Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression Cell Oncol. (Dordr) 43 6 2020 1099 1116 32710433
77 Schwed-Gross A. Hamiel H. Faber G.P. Angel M. Ben-Yishay R. Benichou J.I.C. Glucocorticoids enhance chemotherapy-driven stress granule assembly and impair granule dynamics, leading to cell death J. Cell Sci. 135 14 2022
78 Wortel I.M. van der Meer L.T. Kilberg M.S. van Leeuwen F.N. Surviving stress: modulation of ATF4-mediated stress responses in normal and malignant cells Trends Endocrinol. Metabol. 28 11 2017 794 806
79 Thomson C.G. Aicher T.D. Cheng W. Du H. Dudgeon C. Li A.-H. Discovery of HC-7366: an orally bioavailable and efficacious GCN2 kinase activator J. Med. Chem. 67 7 2024 5259 5271 38530741
80 Tameire F. Wojnarowicz P. Dudgeon C. Fujisawa S. Huang S. Reilly O.B. Abstract 6231: activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models Cancer Res. 83 7_Supplement 2023 6231
81 Drees J. Chan A.S. Li Y. Kangas T. Zhang W. Fumagalli M. 1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells J. ImmunOther Cancer 10 Suppl 2 2022 A1378 -A
82 Ge L. Chen W. Cao W. Liu G. Zhang Q. Zhuang J. GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma Cancer Biomark. 22 3 2018 395 403 29865032
83 Lee J. Keam B. Kim S. Heo J.N. Joung E. Kim M. The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines Transl. Oncol. 27 2023 101592
84 Halbrook C.J. Thurston G. Boyer S. Anaraki C. Jimenez J.A. McCarthy A. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells Nat. Cancer 3 11 2022 1386 1403 36411320
85 Munn D.H. Sharma M.D. Baban B. Harding H.P. Zhang Y. Ron D. Mellor A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase Immunity. 22 5 2005 633 642 15894280
86 Van de Velde L-A Guo X.-Z.J. Barbaric L. Smith A.M. Oguin T.H. Thomas P.G. Murray P.J. Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing Cell Rep. 17 9 2016 2247 2258 27880901
87 Rashidi A. Miska J. Lee-Chang C. Kanojia D. Panek W.K. Lopez-Rosas A. GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma Cancer Immunol. Immunother. 69 2020 81 94 31844909
88 Paul M.S. Saibil S.D. Kates M. Han S. Lien S.C. Laister R.C. Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy Cell Reports Med. 5 3 2024
89 Szaruga M. Janssen D.A. de Miguel C. Hodgson G. Fatalska A. Pitera A.P. Activation of the integrated stress response by inhibitors of its kinases Nat. Commun. 14 1 2023 5535 37684277
90 Angel M. Fleshler E. Atrash M.K. Kinor N. Benichou J.I.C. Shav-Tal Y. Nuclear RNA-related processes modulate the assembly of cytoplasmic RNA granules Nucleic. Acids. Res. 2024
91 Tombari C. Zannini A. Bertolio R. Pedretti S. Audano M. Triboli L. Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth Nat. Commun. 14 1 2023 6777 37880212
92 Skrott Z. Mistrik M. Andersen K.K. Friis S. Majera D. Gursky J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 Nature 552 7684 2017 194 199 29211715
93 Kanellis D.C. Zisi A. Skrott Z. Lemmens B. Espinoza J.A. Kosar M. Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET Cell Death. Differ. 30 7 2023 1666 1678 37142656
94 Broer A. Gauthier-Coles G. Rahimi F. van Geldermalsen M. Dorsch D. Wegener A. Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells J. Biol. Chem. 294 11 2019 4012 4026 30635397
95 Gauthier-Coles G. Rahimi F. Broer A. Broer S. Inhibition of GCN2 reveals synergy with cell-cycle regulation and proteostasis Metabolites 13 10 2023
96 Xue Y. Lu F. Chang Z. Li J. Gao Y. Zhou J. Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade Nat. Commun. 14 1 2023 4758 37553341
97 Carlson K.R. Georgiadis M.M. Tameire F. Staschke K.A. Wek R.C. Activation of Gcn2 by small molecules designed to be inhibitors J. Biol. Chem. 299 4 2023
98 Lough L. Sherman D. Beccera-Flores M. Lavinda O. Ni E. Wang H. Triazolo[4,5-d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells Comput. Struct. Biotechnol. J. 16 2018 350 360 30364637
99 Fujimoto J. Kurasawa O. Takagi T. Liu X. Banno H. Kojima T. Identification of novel, potent, and orally available GCN2 inhibitors with type i half binding mode ACS. Med. Chem. Lett. 10 10 2019 1498 1503 31620240
100 Li M. Teater M.R. Hong J.Y. Park N.R. Duy C. Shen H. Translational activation of ATF4 through mitochondrial anaplerotic metabolic pathways is required for DLBCL growth and survival Blood Cancer Discov. 3 1 2022 50 65 35019856
101 Kato Y. Kunimasa K. Takahashi M. Harada A. Nagasawa I. Osawa M. GZD824 inhibits GCN2 and sensitizes cancer cells to amino acid starvation stress Mol. Pharmacol. 98 6 2020 669 676 33033108
